|  | Mean |  |  |  |  |  | |
---|---|---|---|---|---|---|---|---|
Continuous Lipid Outcome | ARV Group | Pre | Post | Unadjusted Post Difference | Model 1* Adjusted Difference | p-value | Model 2** Adjusted Difference | p-value |
HDL-c (mg/dL) | EFV | 39 | 46 | Ref | Ref | Â | Ref | Â |
 | Unboosted TAZ | 39 | 42 | -4 | -3.92 | 0.003 | -3.43 | 0.008 |
 | Boosted TAZ | 38 | 41 | -5 | -4.12 | <0.001 | -4.00 | <0.001 |
Non- HDL-c (mg/dL) | EFV | 131 | 136 | Ref | Ref | Â | Ref | Â |
 | Unboosted TAZ | 117 | 131 | -5 | -1.92 | 0.55 | -1.08 | 0.73 |
 | Boosted TAZ | 126 | 125 | -11 | -5.75 | 0.01 | -4.57 | 0.04 |
TC/HDL | EFV | 4.45 | 4.02 | Ref | Ref | Â | Ref | Â |
 | Unboosted TAZ | 4.45 | 4.10 | 1.99 | 4.41 | 0.14 | 3.94 | 0.19 |
 | Boosted TAZ | 4.10 | 3.97 | -1.24 | 2.62 | 0.21 | 3.40 | 0.11 |
 |  | Prevalence |  |  |  |  |  | |
Binary Lipid Outcome | ARV Group | Pre | Post | Unadjusted Post Prevalence Ratio | Model 1* Adjusted Prevalence Ratio | p-value | Model 2** Adjusted Difference | p-value |
HDL<40 (mg/dL) | EFV | 52% | 33% | Ref | Ref | Â | Ref | Â |
 | Unboosted TAZ | 55% | 39% | 1.18 | 1.05 | 0.79 | 1.01 | 0.95 |
 | Boosted TAZ | 53% | 42% | 1.27 | 1.18 | 0.18 | 1.19 | 0.17 |
TC<200 (mg/dL) | EFV | 74% | 62% | Ref | Ref | Â | Â | Â |
 | Unboosted TAZ | 85% | 73% | 1.18 | 1.07 | 0.59 | 1.05 | 0.71 |
 | Boosted TAZ | 81% | 78% | 1.26 | 1.16 | 0.09 | 1.13 | 0.16 |